Kutatási jelek – Signal Engine

• Assessment of Clinical Time Intervals Along the Patient Journey with Overall Survival in Localized Osteosarcoma and Ewing Sarcoma: A 20-Year Tertiary Sarcoma Centre Experience — Ewing sarcoma
• Discordant Antitumor Efficacy with Compromised Survival in High‑Risk Unresectable Hepatocellular Carcinoma — Hepatocellular carcinoma
• A Computational Histology Artificial Intelligence Prognostic Biomarker in Non‑Small Cell Lung Cancer Using the Cancer Genome Atlas — NSCLC
• Small-Cell Lung Cancer Research Gets a Boost — SCLC
• Regional Differences in the Clinical Presentation of Registry-Recorded Renal Cell Carcinoma and Area-Level Healthcare Resource Indicators: A Multicenter Study in Miyazaki, Japan — Renal cell carcinoma
• Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study — Prostate cancer
• The Value of Adjuvant Radiotherapy in the Treatment of Melanoma: A Multi-Center Analysis — Melanoma
• Systemic Melanoma Therapy in Patients with Pre-Existing Heart Failure: An HF-Centered Decision Framework and Critical Narrative Review — Melanoma
• Multiple High-Risk HPV Infections and Opportunistic HPV Prevalence Among Women Aged 18–25 Years with NILM, ASC-US, or LSIL Cytology — Cervical cancer
• The Osteosarcoma Tumor Microenvironment: From Cellular Interactions to Advanced Preclinical Models — Osteosarcoma
• Amanitin-Based Fc-Small Molecule‑Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy — Prostate cancer
• Advancing Prostate Cancer Survivorship through Transatlantic Consortium Science: The iCCaRE Initiative — Prostate cancer
• 67 Limited-stage small cell lung cancer — SCLC
• Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC — NSCLC
• Alectinib Beats Crizotinib in Frontline ALK+ NSCLC ALEX Trial — NSCLC
• Dostarlimab Plus Chemotherapy Meets ORR End Point in Metastatic Nonsquamous NSCLC — NSCLC
• Clear cell kidney cancer gene mutation identified in multicenter study — Renal cell carcinoma
• Patient‑Level KRAS G12C Prevalence among Hispanic/Latino and Non‑Hispanic White Patients in Real‑world Clinicogenomic Cohorts — NSCLC
• Molecular Markers and Prior Treatment Inform Maintenance PARP Inhibition in Ovarian Cancer — Ovarian cancer
• Impact of Metastatic Patterns on First-Line Therapy in metastatic renal cell carcinoma (mRCC): Meet-URO 33 — Renal cell carcinoma